A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
收藏DataCite Commons2025-11-04 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00004801/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The AC-065A302 (GRIPHON) study is an event-driven Phase 3 study to demonstrate the effect of selexipag on time to first morbidity or mortality event in patients with pulmonary arterial hypertension.
提供机构：
Vivli
创建时间：
2019-09-19
